

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EPS Creative Health Technology Group Limited

(Incorporated in the Cayman Islands with limited liability)

(HKEX Stock code: 3860)

PROFIT WARNING

This announcement is made by EPS Creative Health Technology Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on a preliminary review of the unaudited financial information of the Group for the year ended 31 March 2023 (the “**Year**”), the Group is expected to record a loss for the year of not less than approximately HK\$42 million for the Year as compared with a loss for the year of approximately HK\$18.4 million for the year ended 31 March 2022.

The Board considers that the increase in loss was mainly attributable to (1) the loss arising from the adoption of merger accounting on the acquisitions as disclosed in the announcements of the Company dated 20 September 2022 and 7 December 2022 in accordance with Accounting Guideline 5 (“**AG5**”) “Merger Accounting for Common Control Combinations” published by the Hong Kong Institute of Certified Public Accountants; and (2) the increase in development costs in the Japan-PRC specialised contract research organisation (CRO) and innovative research organisation (IRO) sectors during the Year.

As the Group’s annual results for the Year have not yet been finalised, the information contained in this announcement is only a preliminary assessment by the management of the Company which is based on the latest financial information currently available, including but not limited to the Group’s unaudited consolidated management account for the Year, which has not been audited by the independent auditors of the Company nor reviewed by the audit committee of the Company as at the date of this announcement and is subject to adjustment upon further review. Accordingly, the actual results of the Group for the Year may be different from what is disclosed in this announcement.

Shareholders and potential investors are advised to read carefully the annual results announcement of the Company for the Year, which is expected to be published by the end of June 2023.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
EPS Creative Health Technology Group Limited
Miyano Tsumoru
Executive Director

Hong Kong, 14 June 2023

As at the date of this announcement, the executive Directors are Mr. Okoso Satoshi, Mr. Miyano Tsumoru, Mr. Gao Feng, Mr. Haribayashi Keikyo and Mr. Maezaki Masahiro; the non-executive Director is Mr. Xia Xiangming; and the independent non-executive Directors are Mr. Taguchi Junichi, Mr. Choi Koon Ming and Mr. Chan Cheuk Ho.